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ABSTRACT
Induced pluripotent stem cells (iPSC) is a novel technology useful for therapeutic and research applications. To date, iPSCs 
is produced through genetic modification that can promote mutation; making it harmful for therapeutic use. Therefore, 
application of non-genetic modification through direct delivery of recombinant proteins aided by protein transduction 
domain (PTD) enable a safer production of iPSC. This study is aimed to establish a stable production of secretable 
recombinant protein via recombination of green fluorescence protein (GFP) and a novel PTD peptide, namely TATκ-GFP. 
293Tcell line was transfected with 20 µg/ml of TATκ-GFP plasmid and the stably transfected 293T cells were then cultured 
for 54 days to determine the stability of expression and secretion of TATκ-GFP recombinant protein in prolonged culture. 
Methylation at the CMV promoter of the TATκ-GFP plasmid was investigated following treatment of transfected cells with 
3 µM/mL of demethylation agent, namely 5-Azacytidine for 72 h in three cycles. Flow cytometry analysis demonstrated 
a transfection efficiency of 9.33% and successful secretion of TATκ-GFP proteins into the culture medium as analysed by 
Western blot at 72 h post-transfection. However, the transfected cells exhibited a decreasing level of GFP expression and 
secretion following prolonged culture with notable stability that only sustained for two weeks. 5-Azacytidine-treated cells 
showed a slight increase of GFP expression compared to non-treated control, suggesting possible promoter methylation 
which could cause instability of TATκ-GFP expression. Conclusively, promoter methylation should be considered for future 
establishment of iPSCs as it could inhibit stable expression and secretion of recombinant proteins.
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ABSTRAK
Sel asal aruhan pluripoten (iPSC) adalah teknologi terkini yang bermanfaat bagi aplikasi perubatan dan penyelidikan. 
Terkini, penghasilan iPSC adalah melalui kaedah pengubahsuaian genetik yang berupaya merangsang mutasi, menjadikan 
ia berbahaya bagi kegunaan perubatan. Justeru, penggunaan kaedah tanpa pengubahsuaian genetik melalui penghantaran 
terus protein rekombinan dengan bantuan domain pentransduksi protein (PTD) membolehkan penghasilan iPSC yang lebih 
selamat. Kajian ini bertujuan untuk membangunkan penghasilan protein rekombinan yang stabil dan terembes melalui 
rekombinasi protein fluoresen hijau (GFP) dan peptida baru PTD iaitu TATκ. Sel selanjar 293T ditransfeksi dengan 20 µg/
mL plasmid TATκ-GFP dan populasi sel dengan transfeksi stabil seterusnya dikultur selama 54 hari untuk mengenal pasti 
kestabilan pengekspresan dan perembesan protein TATκ-GFP pada tempoh pengkulturan yang berpanjangan. Kehadiran 
proses pemetilan pada promoter CMV plasmid TATκ-GFP dikaji melalui rawatan ke atas sel ditransfeksi plasmid dengan 
3 µM/mL agen pengenyahmetilan 5-Azasitidin selama 72 jam bagi tiga kitaran. Analisis sitometri aliran menunjukkan 
kecekapan transfeksi sebanyak 9.33% dan kejayaan protein TATκ-GFP dirembeskan ke dalam media pengkulturan 
berdasarkan analisis Western Blot selepas 72 jam transfeksi. Namun, sel ditransfeksi mempamerkan penurunan 
pengekspresan dan perembesan protein GFP pada tempoh pengkulturan yang berpanjangan dengan kestabilannya 
didapati hanya bertahan selama dua minggu. Sel terawat 5-Azasitidin menunjukkan terdapatnya sedikit peningkatan 
pengekspresan GFP berbanding sel kawalan tanpa rawatan yang mencadangkan kemungkinan kehadiran pemetilan 
pada promoter yang boleh menyebabkan ketidakstabilan pengekspresan TATκ-GFP. Kesimpulannya, pemetilan promoter 
perlu diberi perhatian pada masa hadapan untuk penghasilan iPSC memandangkan ia berupaya merencat kestabilan 
pengekspresan dan perembesan protein rekombinan.




Pluripotent stem cells are master cells that can give rise to 
any cell type that makes up human body. One of the main 
sources for pluripotent stem cells is embryonic stem cells. 
First isolation of human pluripotent stem cell by Thomson et 
al. (1998) had opened a new avenue for the potential use of 
the pluripotent stem cell in medical applications especially 
for regeneration of cells and tissue. However, destruction of 
human embryos for the isolation of embryonic stem cells 
raises ethical issues (Deng 2010; Martinez et al. 2011).
 In 2006, Takahashi and Yamanaka successfully 
reprogrammed somatic mouse fibroblast cells into 
pluripotent stem cells. They have introduced four types 
of transcription factors which are known as Yamanaka 
factors or the magical factors (Oct 3/4, Sox2, c-Myc and 
Klf4) into mouse fibroblast cells via retroviral transduction. 
This method had triggered the mouse fibroblast cells to 
undergo cellular reprogramming into pluripotent stem 
cells, or widely regardless induced pluripotent stem cells 
(iPSC). Subsequently, establishment of iPSC from human 
fibroblast was also successfully achieved (Takahashi et al. 
2007). This technology has become a breakthrough as it 
overcomes the need to use the human embryos which is 
unethical. Furthermore, immune rejection is preventable 
since iPSC created using patient’s own adult stem cells. In 
addition to the therapeutic potential, iPSC is also beneficial 
as a research tool to study various aspects of diseases, drug 
development and toxicology testing (Deng 2010; Han et 
al. 2010; Leeper et al. 2010; Martinez et al. 2011; Stadfeld 
& Hochedlinger 2010; Yoshida & Yamanaka 2010). 
 However, iPSC technology faces few constraints due to 
genetic manipulation. It is believed that insertion of virus 
vector that used to deliver the four transcription factors could 
permanently modify the host genome and subsequently 
lead to genetic mutation, which can increase the risk of 
tumorigenicity (Cho et al. 2010; Fazlina Nordin 2014; 
Han et al. 2010; Martinez et al. 2011; Okano et al. 2013; 
Yamanaka 2009; Yoshida & Yamanaka 2010). Therefore, 
this strategy remains unacceptable for clinical trials due to 
safety reasons. One of the alternative ways to overcome this 
concern is to deliver fusion proteins of these transcription 
factors using protein transduction domain (PTD) (Kim 
et al. 2009; Zhang et al. 2012; Zhou & Zhang 2013).
 Protein transduction is defined as the introduction of 
proteins exogenously into target cells owing to their ability 
to penetrate the cell membrane and further uptake by the 
target cells (Ford et al. 2001). Translocation property of a 
protein is determined by the presence of short amino acid 
sequences within the proteins, namely protein transduction 
domains (PTDs); which is fundamental in mediating cellular 
entry (Beerens et al. 2003). The most widely studied PTDs 
are the HIV TAT protein, homeodomain of Drosophila 
antennapeptide (AntpHD) and the herpes simplex virus VP22 
protein (Beerens et al. 2003; Ford et al. 2001; Noguchi & 
Matsumoto 2006b). PTDs possess a number of features that 
making them a promising candidate in mediating delivery of 
therapeutic proteins in a safe manner. These features include 
their ability to deliver macromolecules including siRNA 
(Katas et al. 2014) efficiently into target cells independently 
of cell types, provide stable transduction, allow precise 
time and dose management as well as confer minimal risk 
of genetic modification of target cells. 
 Among PTDs, the HIV TAT has been the most widely 
studied and a number of modifications of its amino acid 
sequence have been done to enhance its transduction 
efficacy and stability. This has led to a number of reports 
of which the improved synthetic TAT demonstrated greater 
transduction efficiency and stability in mediating delivery of 
several peptides and proteins into target cells as compared 
to its original TAT sequence (Noguchi & Matsumoto 2004). 
In the present study, a novel synthetic TAT sequence, namely 
TATκ was studied. TATκ was established by introducing 
mutations to displace the two furin cleavage sites (RQRR 
and RKKR) within the native TAT peptide to enhance the 
bioavailability of the cargo (Flinterman et al. 2009).
 In the context of IPSC, recombinant protein that resulted 
from conjugation of PTD and reprogramming factors 
enhances transduction and translocation of protein into target 
cell. This new technique yields non-genetically modified, 
IPSC. Furthermore, Kim et al. (2009), has produced human 
IPSC by using arginine as PTD to deliver Yamanaka factors 
into human newborn fibroblast (HNF) cells. Then, Zhang 
et al. (2012) further exploited TAT-PTD and 11 Arginine 
(R)-PTD to reprogramme human fibroblast into iPSC.
 In this present research, the 293T cell line was selected 
as mammalian expression system for the establishment 
and secretion of combined protein TATκ-PTD and Green 
Fluorescent Protein (GFP). The novelty of current study 
is relying on the technology of recombinant protein 
production utilizing eukaryotic cells as producer cells for 
expression and secretion of recombinant protein. This 
approach can be considered novel as previous effort for 
recombinant protein technology in iPSCs only limited to 
protein produced by prokaryotic system which require 
purification prior to application. To date, there is no study 
concerning the efficiency of TATκ recombinant proteins 
to reprogramme differentiated cells into iPSC has been 
reported. Thus, the use of newly synthesized PTD peptide 
namely TATκ which claimed to have better PTD property 
(Flinterman et al. 2009; Nordin et al. 2014) is another 
novelty factor. Although recombinant protein technology 
is safer than genetic modification strategy, it has a number 
of limitations including stability and yield. Therefore, the 
stability of production and secretion of recombinant protein 
TATκ-GFP in 293T cell will be studied in terms of cultivation 
period and methylation activity of transcription promoter.
MATERIALS AND METHODS
CELL CULTURE
293T cell line were cultured and maintained in DMEM 
(Invitrogen) with 25 mM glucose, 10% fetal bovine serum 
(FBS, Invitrogen) and 1 mM sodium pyruvate under 5% 
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CO2 at 37°C. A different density of cells was used as 
optimized depending on the size of the culture plate in 
each experiment. 
GENERATION OF TATΚ-GFP STABLE CELL LINE
293T cells (1.0 × 106) were seeded in 10 mL DMEM 
complete medium in 100 mm diameter culture dish. A 
standard protocol for calcium phosphate (CaCl2) was 
performed with modifications (Fazlina et al. 2016). On 
day 3 of culture, a total of 1 mL of transfection mixture 
containing 20 µg of plasmid DNA, 0.5 M CaCl2 and 2× 
HEBSS (HEPES Buffered Saline Solution) at pH6.7 were 
incubated at room temperature for 30 min and added 
dropwise to the plated 293T cells. The culture medium 
was replaced with fresh complete medium on the following 
day and the cells were further incubated at 37°C for 72 h. 
Following 72 h post-transfection, the transfected cells were 
further treated with Puromycin (2.5 µg/mL). Complete 
growth media with or without puromycin was changed 
every 3-4 days and clones were picked after 3 to 4 weeks. 
Non-transfected 293T cell line will be used as negative 
control for each experiment. 
LONG TERM CULTURE
Stable cell lines obtained were cultured in 6 well culture 
dish with 5.0 × 105 cells per well. Cells were maintained and 
complete medium with or without puromycin (DMEM with 
10% FBS) were changed every 3-4 days. Cells were split 
after they are 80% confluent and culture were continued 
for 54 days before the experiment was terminated. The 
second round of transfection will be performed at Day 
36 to enhance the GFP expression. Whole cell lysate and 
culture supernatant were collected at day 32, 43 and 50 
and subjected to immunoblotting.
IMMUNOBLOTTING
For immunoblotting, cells were washed and lysed in RIPA 
buffer (Sigma Aldrich) and 1× protease inhibitor. Lysates 
were further clarified with centrifugation at 10,000 rpm 
for 10 min. Gel electrophoresis was done using Bolt Bis-
Tris plus 4-12% (Invitrogen) before transfered on PVDF 
membrane (GE). Immunoblotting were performed with 
5% skim milk powder in 0.1% Tween PBS. For sample 
preparations from cell supernatants, cell culture medium 
was collected and secreted proteins were concentrated 
using Viva Spin (GE) for 15 min at 3,000 rpm. A standard 
protocol for antibody staining was performed with slight 
modifications (Fazlina et al. 2016). The following primary 
antibodies were used: 1/1000 dilution of anti-rabbit GFP 
polyclonal antibody (Cell Signalling Technology, US) 
and 1/1000 dilution of anti-mouse α-Tubulin monoclonal 
antibody (Sigma, Aldrich). The following secondary 
antibodies were used; 0.2 µg/mL goat anti-mouse IgG 
(Sigma) horseradish peroxidase and 0.2 µg/mL goat anti-
rabbit polyclonal horseradish peroxidase (Santa Cruz 
Biotech.).
DNA DEMETHYLATION
After 54 days of culture, stable cell lines were cultured 
in 6-well plate (1.0 × 106 cells per well) and 3 cycles of 3 
µmM of 5-Azacytidine (Sigma Aldrich) treatments were 
conducted. Each cycle of treatment consists of treatment 
with 3 µmM 5-Azacytidine for 72 h followed by 11 days 
of treatment-free culture for 6 weeks.
FLOW CYTOMETRY
5-Azacytidine treated and non-treated cells (1.0 × 106 cells) 
were collected and washed in 1× PBS (Gibco) and the GFP 
expression was analysed using FACS Calibur.
STATISTICAL ANALYSIS
Sample means between control and treatment conditions 
were compared by paired t-test using Prism Graph software 
version 5. The data were confirmed to be normally 
distributed and had similar variance as estimated by SEM 
(n=3). Data were concluded to be significant with P value 
of p<0.05.
RESULTS
293T-TATΚ-GFP STABLE MIXED POPULATION SHOWS A 
DECREASED EXPRESSION OF TATΚ-GFP RECOMBINANT 
PROTEIN IN PROLONGED CULTURE
Figure 1 shows the stability expression study of 293T-TATκ-
GFP. The transfected 293T were treated with puromycin at 
72 h post-transfection to select for stable mixed population 
which are puromycin resistant. The transfected 293T 
were continuously cultured up to day 54 (D54) before the 
experiment was terminated. A second transfection was 
performed at day 36 (D36) on the stable mixed population 
to enhance the recombinant protein expression.
 FACS analysis showed that the expression level of GFP 
in transfected 293T cells decreases in prolonged culture 
(Figure 2). Data shown is an average percentage ± S.E.M 
of triplicate independent samples. The GFP expression was 
9.33±0.295% at 72 h post-transfection (Day 3). A second 
round of transfection on Day 36 (D36) were able to restore 
the expression and TATκ-GFP protein was detected at day 
43 (D43) with 39.16±0.384 percent, which was higher as 
compared to the first transfection. However, it was not 
statistically significant (p<0.05). The same population of 
the selected cells were further cultured and analysed on 
day 50 (D50) with decreased GFP expression, 2.19±0.140%. 
Fluorescence microscopy analysis shows reduce number of 
the GFP positive cells with agreement to FACS data (Figure 
3). Visually, the numbers of GFP positive cells reduce 
periodically after two weeks of culture to only a few GFP 
positive cells up to Day 30, after first transfection (Figure 
3(A)). A similar pattern of GFP expression as in the first 
transfection was observed up to Day 50, after second round 
of transfection (Figure 3(B)). Overall, the data shows that 
the selections of mixed population for establishment of 
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The expression and secretion of TATκ-GFP recombinant protein was observed up to Day 54 before the experiment was 
terminated 
FIGURE 1. Stability expression study of 293T-TATκ-GFP mixed population
FACS analysis showed that the expression level of GFP in transfected 293T cells decreases in prolonged culture. Notably the 
level of GFP expression was increased at day 43 after second round of transfection and decreased by day 50. Data were not 
statistically significant (p>0.05). A total of 1 × 106 cells were cultured in a complete growth medium and further transfected with 
plasmid encoding TATκ-GFP sequence. The TATκ-GFP expression was determined at 72 h post-transfection following selection 
of stable mixed population with 2.5 μg/mL puromycin at day 43 and day 50. Data shown are the mean±SEM of triplicate from 
independent experiments
FIGURE 2. The level of TATκ-GFP expression in the transfected 293T-TATκ-GFP by FACS analysis
The number of GFP positive cells was reduced up to day 32 after first transfection (3A). A similar pattern of GFP positive cells 
was observed after second transfection (3B). These data are in line with FACS analysis as shown in Figure 2. Approximately 72 h 
(Day 3) post-transfection, cells were further treated with 2.5 μg/mL puromycin for selection of stable mixed population. A second 
transfection was performed at Day 36 following puromycin treatment. The expression of TATκ-GFP recombinant protein was 
observed up to day 54 before the experiment was terminated. A green fluorescence indicates the presence of GFP or TATκ-GFP 
recombinant protein in the transfected 293T cells. Magnifications at 10×
FIGURE 3. Fluorescence microscopy analysis of 293T-TATκ-GFP cells in prolonged culture
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producer cell secreting TATκ-GFP are potentially achieved. 
293T-TATκ-GFP Stable Mixed Population Has Lost the 
Ability to Secretes TATκ-GFP Recombinant Protein in 
Prolonged Culture
 Figure 4 shows the expression and secretion of TATκ-
GFP recombinant protein at 72 h (Day 3) post-transfection 
by Western Blot analysis. Both cell lysate and culture 
supernatant (sup) of transfected 293T cells were further 
analysed at Day 3 post-transfection.
 TATκ-GFP recombinant protein was present in both 
samples as indicated by prominent bands at approximately 
35 kD of protein weight as compared to non-transfected 
293T (Control) (Figure 4). This finding is consistent with 
data by fluorescent microscopy analysis, whereby bundle 
of GFP positive cells were present at Day 3 post-transfection 
(Figure 3(A)).
FACS analysis. The data was expressed in percentage ± 
S.E.M of triplicate independent samples. Non-treated 
samples were served as control.
 Figure 6 shows the effect of 5-AzaC treatment on GFP 
expression of 293T-TATκ-GFP stable mixed population. 
Relatively, the expression of TATκ-GFP was increased 
at week 2, after first cycle of treatment as compared to 
control. However, this data was not statistically significant 
(p<0.05). Subsequently, the expression level was 
constantly decreased from week 3 to week 6 before the 
experiment was terminated (p<0.05). Overall, the stable 
mixed population was able to restore the expression but 
eventually lost its ability to express and secrete TATκ-GFP 
due to prolonged culture even with repeated treatment of 
5-AzaC.
TATκ-GFP recombinant protein was present in cell lysates (duplicate samples) and 
sup as indicated by prominent bands at approximately 35 kD of protein weight as 
compared to non-transfected 293T (Control). A total of 3 × 106 cells were lysed 
and 10 mL of culture supernatant (sup) was concentrated via spin column. Cell 
lysate and sup from non-transfected 293T cells were used as negative (-ve) control. 
Cell lysate from 293T cells transiently transfected with GFP plasmid (with prior 
confirmation of GFP expression) was used as positive (+ve) control. A prominent 
band approximately at 35 kDa (red box) indicated the presence of TATκ-GFP 
recombinant protein as confirmed by positive control
FIGURE 4. Western blot validation of TATκ-GFP expression and 
secretion of 293T-TATκ-GFP at 72 h post-transfection
  Following puromycin treatment, the expression of 
TATκ-GFP recombinant protein was only detectable in cell 
lysate of selected mixed populations as confirmed by 
Western Blot analysis (faint bands) at Day 32 and Day 50 
(Figure 5). However, there was no secretion of the TATκ-
GFP recombinant protein was observed in both sups (Day 32 
and Day 50). A second transfection was performed at Day 
36 (D36), which was able to restore TATκ-GFP recombinant 
protein expression but not its secretion as shown at Day 
43 (D43) (Figure 5). 
5-AZACYTIDINE (5-AZAC) TREATMENT WAS ABLE TO 
RESTORE THE EXPRESSION OF TATΚ-GFP RECOMBINANT 
PROTEIN IN 293T-TATΚ-GFP STABLE MIXED POPULATION
The stable mixed population was further treated with 3 μg/
mL 5-AzaC (demethylation agent) in three cycles for six 
weeks. Briefly, cells were cultured with medium containing 
5-AzaC for three days following 11 days in agent-free 
medium (standard growth medium). This culture process 
was repeated for 3 cycles over a period of six weeks. The 
viable cells were further analysed for GFP expression by 
The expression of TATκ-GFP recombinant protein was only just detectable in cell 
lysates of selected mixed populations as confirmed by Western Blot analysis (faint 
bands) at Day 32 and Day 50 but not in their sups. The prominent band at Day 43 
indicated the high expression of TATκ-GFP recombinant protein in the cell lysate 
after second round of transfection without secretion in the sup. A total of 3 × 106 
cells were lysed and 10 mL of culture supernatant (sup) was concentrated via spin 
column. Cell lysate and sup from non-transfected 293T cells were used as negative 




FIGURE 5. Western blot validation of TATκ-GFP expression and 
secretion of stable mixed population of 293T-TATκ-GFP
FACS analysis shows that treatment with 5-AzaC was able to restore the expression 
of TATκ-GFP recombinant protein of stable mixed population but eventually lost 
its ability due to prolonged culture. Data were not statistically significant (p>0.05). 
A total of 5 × 105 cells were culture in medium containing 3 µg/mL of 5-AzaC 
for 3 cycles over a six weeks period. The non-treated stable mixed population of 
293T-TAT
ƙ
-GFP cell was used as negative control. Data shown are the mean±SEM 
of triplicate from independent experiments
FIGURE 6. The level of TATκ-GFP expression in the stable 
mixed population of 293T-TATκ-GFP by FACS analysis
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DISCUSSION
A previous study by the same group, Nordin et al. (2014), 
have demonstrated the establishment of Oct-3/4 and 
KLF4 proteins fused to TATκ domain producer cells. These 
producer cells were able to express and secrete recombinant 
proteins and successful uptake by the targeted cell lines. 
Another study also has reported the ability of novel 
TATκ fusion proteins to efficiently transduced target cells 
(Flinterman et al. 2009). A synthetic TATκ domain, which 
was developed by this group, has been shown to allow 
the secretion and subsequent uptake by target cells of GFP 
(protein marker) and apoptin (tumour-specific cytotoxicity 
protein) to induce cell death in tumour cells. 
 In this present study, the transient expression and 
secretion of TATκ-GFP has been successfully confirmed. 
In addition, a stable mixed population (producer cells) 
secreting TATκ-GFP has been established. However, we 
discovered a reduction of GFP expression in these stable 
producer cells in prolonged culture, resulting in low 
secretion of TATκ-GFP as analysed by Western blot. Further 
investigation has demonstrated that treating these producer 
cells with a de-methylation agent, 5-azacytidine (5-AzaC) 
could restore GFP expression and secretion into culture 
medium, suggesting methylation of the cytomegaloviral 
(CMV) promoter being the cause of reduced expression of 
GFP in long-term culture. It has often been reported that in 
stably transfected cells, the CMV immediate early promoter 
can be silenced by methylation during continous in vitro 
culture (Grassi et al. 2003).
 In adult somatic tissues, methylation typically occurs 
at CpG nucleotides, where there is a high content of C 
and G bases (Grassi et al. 2003; Hsu et al. 2010; Mariati 
et al. 2014). DNA methylation is known to inhibit gene 
expression, resulting in decreased protein expression (Elias 
et al. 2013). The cytomegalovirus (CMV) promoter is one 
of the most widely used for gene expression and protein 
secretion in mammalian expression vectors. This promoter 
DNA sequence encoded 33 CpG nucleotides which is prone 
to methylation (Moritz et al. 2015). CMV promoter has 
been reported to give strong expression of target genes 
in a variety of mammalian cell types (Cheng et al. 2004). 
Nevertheless, protein expression driven by the CMV 
promoter in most transfected mammalian cell lines shows 
a continous decrease due to extensive methylation of this 
promoter (Brooks et al. 2004). However, this gene silencing 
can be re-activated by treating the cells with demethylating 
agents such as 5-AzaC. This agent causes demethylation of 
target genes by removing the methyl-group from the CMV 
promoter, allowing higher level expression of the target 
gene. 
 Interestingly, this stable mixed population gradually 
lost its ability to express TATκ-GFP in continuous culture up to 
week six even after 5-AzaC treatment, thus suggesting that 
the treated cells has biologically tolerate the concentration 
of given 5-AzaC. A few factors may contribute to 5-AzaC 
tolerance which is: low level of cytidine kinase enzyme 
activation; high level of detoxification of cytidine 
deaminase enzyme (Michalowsky & Jones 1987); and less 
integration of methylation agent into DNA. Biologically, 
5-Azacytidine will undergo phosphorylation mediated by 
uridine-cytidine kinase enzymes (UCK1 and UCK2) to form 
5-Aza-2’-deoxycytidine triphosphate by ribonucleotide 
reductase (RNR) (Saunthararajah 2013). Thus, less activity 
mediated by either UCK1 or UCK2 will affect the 5-AzaC 
methylation activity. Detoxification of 5-AzaC happens 
through biology reaction of cytidine deaminase produced 
by liver cells. In addition, incorrect site integration 
of 5-AzaC with nucleotide sites of CpG island within 
promoter sequence will also reduce methylation activity 
(Michalowsky& Jones 1987). This issue perhaps can be 
resolved by increase the concentration of the methylation 
agent used.
 Additionally, Western blot analysis of culture 
medium of 293T-TATκ-GFP stable mixed population at 
day 43 (after second transfection) failed to detect band 
which confirmed the absent of TATκ-GFP secretion. This is 
probably due to very low concentration of secreted protein 
in culture medium, or the recombinant protein could not be 
secreted. Post-translational modifications of protein in the 
eukaryotic/mammalian expression system can caused the 
cleavage of signal peptide which is important to enhance 
protein movement into endoplasmid reticulum for secretion 
(Hedge & Bernstein 2006). This could explain the absence 
of recombinant protein in the culture medium although it 
is being expressed at gene level. Contrary, Koutsokeras et 
al. (2014) reported that PTD fused to protein of interest is 
the culprit that inhibit the secretion of the protein itself.
 When taken together with previous reports 
demonstrating that 293T cells can be readily maintained 
in vitro for protein secretion, these data have confirmed 
previous study by Nordin et al. (2017) that such systems 
may be adaptable to human therapy. Moreover, current 
studies have confirmed the ability of TATκ fusion proteins 
to enter target cells and biologically functional in the 
case of TATκ-Oct-3/4 (Nordin et al. 2014). Fundamental 
understanding of immunogenicity, protein half-life, protein 
concentration and modes of delivery are important in order 
to be potentially considered for long-term and effective 
human applications (Nordin et al. 2017). Until now, it is 
unclear how proteins behave when interacting with the cell 
membrane to mediate entry. In theory, protein transduction 
across the cellular membrane results in partial unfolding of 
the protein which may differ from one protein to another 
(Schwarze et al. 2000). The transduced proteins become 
biologically functional, once refolding inside the target 
cells (Bonifaci et al. 1995). Also animal studies can be 
conducted to further investigate the phenotypic changes 
to determine how promising in vivo protein transduction 
to deliver factors for iPSC reprogramming. 
 Generally, few improvements could be further 
explored in the future: to establish a producer cell from a 
single clone that could be stably secrete TATκ recombinant 
proteins in prolonged culture; to further investigate the 
DNA methylation profile of the CMV promoter that derived 
the TATκ recombinant protein expression; to consider a 
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different methylation agent which is non-toxic to cells; and 
to produce sufficient of physiological levels of secreted 
proteins for large scale studies. 
CONCLUSION
In conclusion, the establishment of 293T-TATκ-GFP stable 
mixed population as a producer cell for continuous secretion 
of iPSC reprogramming factors is possible. However, these 
stable mixed population demonstrated a reduce expression 
level of recombinant protein in prolonged culture. 5-AzaC 
treatment could help to restore the protein expression but 
not its secretion, suggesting DNA methylation of the CMV 
promoter. Therefore, understanding and improving the 
mechanisms involved in the direct delivery of TAT fusion 
proteins into target cells should provide an alternative and 
safe platform to generate iPSC which could benefits the 
therapeutic applications.
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